NRT6003 / Chengdu New Radiomedicine Technology - LARVOL DELTA

Safety and Efficacy of TareSphere Injection and cTACE in Patients With Unresectable HCC (clinicaltrials.gov) - P3 | N=108 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

A Multicentre, Prospective, Open-label Randomised Controlled Clinical Study Comparing the Efficacy and Safety of NRT6003 Injection and Traditional Meridian Embolism in Patients with Non-operable Hepatocellular Cancer in China (clinicaltrials.gov) - P3 | N=6 | Not yet recruiting | Sponsor: Zhongda Hospital

New P3 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Safety and Efficacy of TareSphere Injection and CTACE in Patients with Unresectable HCC (clinicaltrials.gov) - P3 | N=108 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.

New P3 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of TareSphere in Patients with Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.

New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor